Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48.
Randomized controlled trial · Liver Int · 2025. Source record refreshed; an explanation has not been reviewed.
About this paper
This page identifies the publication and its source. A checked explanation of its findings is not yet available.
Reading this record
Checking bibliographic metadata does not verify a study’s conclusions or any advice previously linked to it.
Publication details
Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48.
Asselah T, Lampertico P, Aleman S et al.
Liver Int · 2025
- PubMed ID
- 39648559
- Record checked
A checked publication record confirms source details. It does not verify a health claim or assess the quality of the study. Our approach.
Keep your place in the research.
Save this source or mark it as read.